clinical trial · NCT07244289

Managed Access Programs for VAY736, Ianalumab

$NVS →·—·available

Primary Immune ThrombocytopeniaSjögren's Syndromeianalumab

brief summary

The purpose of this registration is to list Managed Access Programs (MAPs) related to VAY736, ianalumab

started

—

primary completion

—

completion

—

last updated

Mar 23, 2026

detailed description

* CVAY736I12003M - Available - Managed Access Program (MAP) Cohort Treatment Plan CVAY736I12003M to provide access to ianalumab (VAY736) for patients with Primary Immune Thrombocytopenia (ITP) * CVAY736A1002M - Available - Managed Access Program (MAP) Cohort Treatment Plan CVAY736A1002M to provide access to ianalumab for adult patients with Sjögren's disease * CVAY736A1003I - Available - Managed Access Program (MAP) Individual Patient Request (IPR) Cover Letter CVAY736A1003I to provide access to Ianalumab (VAY736) for Sjögren's Disease * CVAY736I12004I - Available - Managed Access Program (MAP) Individual Patient Request (IPR) Cover Letter CVAY736I12004I to provide access to Ianalumab (VAY736) for Primary Immune Thrombocytopenia (ITP) and Evans syndrome

full record on clinicaltrials.gov ↗

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol